Precision Biotech Taiwan Corp
Pioneers in cancer immunotherapy
About Precision Biotech Taiwan Corp
Precision Biotech Taiwan Corp., established on December 6, 2017, is a biotechnology firm specializing in the development and clinical application of immune cell therapies for cancer patients. The company operates within the advanced therapy medicinal products (ATMP) sector, focusing on regenerative medicine and oncology. Its establishment was the culmination of a three-year process of discussion and due diligence between scientific and commercial partners, aiming to integrate capital, technology, and expertise.
The company's business model is centered on the research, development, and provision of cell-based therapeutic products. Its primary clients are hospitals and, by extension, cancer patients. Revenue is generated through the clinical use of its cell preparations, which are supplied to several major hospitals in Taiwan, including Kaohsiung Medical University Chung-Ho Memorial Hospital, Tungs' General Hospital, Kuang Tien General Hospital, and Taipei Chung Shan Hospital, under specific regulatory approvals. The company has received backing from accelerators and incubators, notably the Hong Kong Science and Technology Park.
Precision Biotech's product pipeline features both autologous (using the patient's own cells) and allogeneic (using donor cells) therapies. Key products include PB101, an autologous immune cell preparation, and PB103, an allogeneic Natural Killer (NK) cell preparation. Both are undergoing clinical trials in Taiwan for treating various solid tumors. The company has established a portfolio of core technologies, patents, and know-how in NK cell and gene-editing, creating a platform for genetically engineering NK/NKT cells. This platform supports a research and development pipeline that includes first-in-class universal cell therapy products targeting lung cancer, liver cancer, and other solid and hematologic tumors.
Significant milestones include being recognized as a biotech and new drug company by Taiwan's Ministry of Economic Affairs. In July 2021, its international arm, Precision Biotechnology International Co., Ltd., gained approval to enter the Hong Kong Science Park, with plans to build a PIC/S GMP-compliant cell preparation facility to serve the Greater Bay Area. Concurrently, its allogeneic NK cell product, PB103, has been prepared in Hangzhou, China, for planned Phase I/II multi-center clinical trials.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Open positions
- None listed
- Dealroom signal
- 18.7/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotechnology, Rumoured $1B, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VCOther financing | Jan 2022 | $181M | $725M | Undisclosed | ↗ |
Growth signals
Latest recorded traffic for Precision Biotech Taiwan Corp is 2.2K monthly website visits, up 37.5% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Precision Biotech Taiwan Corp in the Taipei ecosystem
The Precision Biotech Taiwan Corp office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Precision Biotech Taiwan Corp on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Precision Biotech Taiwan Corp’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










